Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001776627 | SCV002013327 | uncertain significance | not provided | 2022-12-02 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Genome Diagnostics Laboratory, |
RCV002276890 | SCV002566219 | uncertain significance | Ehlers-Danlos syndrome | 2020-06-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002422843 | SCV002724515 | uncertain significance | Cardiovascular phenotype | 2024-05-23 | criteria provided, single submitter | clinical testing | The p.Q70R variant (also known as c.209A>G), located in coding exon 1 of the TNXB gene, results from an A to G substitution at nucleotide position 209. The glutamine at codon 70 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002489825 | SCV002793592 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2021-12-09 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001776627 | SCV005412123 | uncertain significance | not provided | 2024-05-20 | criteria provided, single submitter | clinical testing |